SRF
|
|
| BOM : 503806     NSE : SRF     | |
| LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Average |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
May 27,2026 |
|
Price(EOD): ₹ 2,738.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Chemicals |
| MCap: ₹ 81,166.18 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SRF | 4.5% | 9.2% | -5.4% |
| SOLAR INDUSTRIES INDIA | 1.5% | 22.3% | 23% |
| PIDILITE INDUSTRIES | 0.6% | 5.8% | -1.3% |
| GUJARAT FLUOROCHEMICALS | -3.9% | 8% | -5.8% |
| GODREJ INDUSTRIES | 2.1% | 13.8% | -2.1% |
| NAVIN FLUORINE INTERNATIONAL | 1.7% | 10.1% | 71.1% |
| DEEPAK NITRITE | -3.8% | 1.9% | -16.6% |
| ATUL | -0.9% | 4.3% | -2.5% |
| TATA CHEMICALS | 2.4% | 7.2% | -8.7% |
FUNDAMENTAL ANALYSIS OF SRF
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SRF
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
44.23
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,835.18 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 5.78
P/B Calculated based on Book Value of Rs 14,041.70 Cr
[Latest Year - Mar2026 - Consolidated Results ] 5.14
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 15,786.50 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
127% 77% 95% |
SHARE PRICE MOMENTUM OF SRF
SRF vs SENSEX
DEBT OF SRF
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.28 0.34 0.33 0.32 |
0.37 0.43 0.42 0.41 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF SRF
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF SRF
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
24.31% 31.5% 67.62% 34.52% |
7% 7.13% 7.03% 10.64% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
SRF related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE COMMODITIES | 3.6% | 5.6% | 17.2% |
| BSE FOCUSED MIDCAP | 3.5% | 6.2% | 8.1% |
| BSE SENSEX NEXT 50 | 2.9% | 2.6% | 4.1% |
| BSE 200 EQUAL WEIGHT | 2.4% | 2.7% | 5.8% |
| BSE 400 MIDSMALLCAP INDEX | 2.3% | 4.2% | 5.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY COMMODITIES | 3% | 3.9% | 20.2% |
| NIFTY INDIA MANUFACTURING | 2.8% | 5.2% | 14% |
| NIFTY MIDCAP150 MOMENTUM 50 | 2.5% | 4.7% | 6.6% |
| NIFTY 500 EQUAL WEIGHT | 2.4% | 3.2% | 4.5% |
| NIFTY500 MULTICAP INDIA MANUFACTURING 50:30:20 | 2.3% | 5.2% | 11.3% |
You may also like the below Video Courses
FAQ about SRF
Is SRF good for long term investment?
As on May 27,2026, the Fundamentals of SRF look Strong and hence it may be good for long term investment! See Financial Performance of SRF . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SRF UnderValued or OverValued?
As on May 27,2026, SRF is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SRF ?
As on May 27,2026, the Intrinsic Value of SRF is Rs. 1,402.00 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,206.39
Fair Value [Median EV / Sales Model] : Rs. 1,549.87
Fair Value [Median Price / Sales Model] : Rs. 1,402.00
Estimated Median Fair Value of SRF : Rs. 1,402.00
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.